Skip Nav Destination
Issues
1 May 2010
-
Cover Image
Cover Image
Interferon regulatory factor-1 (IRF1) can function as a tumor suppressor in breast cancer by regulating the balance of prosurvival and proapoptotic factors. Loss of IRF1 is an important characteristic of breast cancer cells that have acquired resistance to antiestrogen therapy, a phenotype that often develops in estrogen receptor-α positive (ER+) breast cancers. Interferon gamma (IFNγ), a type II interferon, can rescue IRF1 expression in antiestrogen-resistant breast cancer cells and restore their sensitivity to antiestrogen-mediated apoptosis. For details, see article by Ning and colleagues on page 1274. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Editorial
Spotlight on Molecular Profiling
Review
Research Articles
AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth
Kyla M. Grimshaw; Lisa-Jane K. Hunter; Timothy A. Yap; Simon P. Heaton; Mike I. Walton; Steven J. Woodhead; Lynsey Fazal; Matthias Reule; Thomas G. Davies; Lisa C. Seavers; Victoria Lock; John F. Lyons; Neil T. Thompson; Paul Workman; Michelle D. Garrett
A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In vitro and In vivo
Kuzhuvelil B. Harikumar; Ajaikumar B. Kunnumakkara; Nobuo Ochi; Zhimin Tong; Amit Deorukhkar; Bokyung Sung; Lloyd Kelland; Stephen Jamieson; Rachel Sutherland; Tony Raynham; Mark Charles; Azadeh Bagherzadeh; Caroline Foxton; Alexandra Boakes; Muddasar Farooq; Dipen Maru; Parmeswaran Diagaradjane; Yoichi Matsuo; James Sinnett-Smith; Juri Gelovani; Sunil Krishnan; Bharat B. Aggarwal; Enrique Rozengurt; Christopher R. Ireson; Sushovan Guha
Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition
Wataru Okamoto; Isamu Okamoto; Takeshi Yoshida; Kunio Okamoto; Ken Takezawa; Erina Hatashita; Yuki Yamada; Kiyoko Kuwata; Tokuzo Arao; Kazuyoshi Yanagihara; Masahiro Fukuoka; Kazuto Nishio; Kazuhiko Nakagawa
Schweinfurthin A Selectively Inhibits Proliferation and Rho Signaling in Glioma and Neurofibromatosis Type 1 Tumor Cells in a NF1-GRD–Dependent Manner
Thomas J. Turbyville; Demirkan B. Gürsel; Robert G. Tuskan; Jessica C. Walrath; Claudia A. Lipschultz; Stephen J. Lockett; David F. Wiemer; John A. Beutler; Karlyne M. Reilly
Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study
Giuseppe Locatelli; Roberta Bosotti; Marina Ciomei; Maria G. Brasca; Raffaele Calogero; Ciro Mercurio; Francesco Fiorentini; Matteo Bertolotti; Emanuela Scacheri; Angela Scaburri; Arturo Galvani; Enrico Pesenti; Thierry De Baere; Jean-Charles Soria; Vladimir Lazar; Antonella Isacchi
Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
Amy K. Keating; Grace K. Kim; Ashley E. Jones; Andrew M. Donson; Kathryn Ware; Jean M. Mulcahy; Dana B. Salzberg; Nicholas K. Foreman; Xiayuan Liang; Andrew Thorburn; Douglas K. Graham
Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer Cells
Maria Serova; Lucile Astorgues-Xerri; Ivan Bieche; Sebastien Albert; Michel Vidaud; Karim A. Benhadji; Shahin Emami; Dominique Vidaud; Pascal Hammel; Nathalie Theou-Anton; Christian Gespach; Sandrine Faivre; Eric Raymond
Expression of Oncogenic Kinase Bcr-Abl Impairs Mitotic Checkpoint and Promotes Aberrant Divisions and Resistance to Microtubule-Targeting Agents
Kamila Wolanin; Adriana Magalska; Monika Kusio-Kobialka; Paulina Podszywalow-Bartnicka; Susanne Vejda; Sharon L. McKenna; Grazyna Mosieniak; Ewa Sikora; Katarzyna Piwocka
The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade
Victoria El-Khoury; Etienne Moussay; Bassam Janji; Valérie Palissot; Nasséra Aouali; Nicolaas H.C. Brons; Kris Van Moer; Sandrine Pierson; Eric Van Dyck; Guy Berchem
17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species
Teneille Walker; Clint Mitchell; Margaret A. Park; Adly Yacoub; Mohamed Rahmani; Dieter Häussinger; Roland Reinehr; Christina Voelkel-Johnson; Paul B. Fisher; Steven Grant; Paul Dent
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.